PD-L1 Expression in Urothelial Carcinoma with Predominant or Pure Variant Histology: Concordance Among Three Commonly Used and Commercially Available Antibodies

The introduction of immune checkpoint blockade (ICB) therapy has transformed the management of advanced bladder cancer (BC). Despite its limitations, PD-L1 immunohistochemistry may serve as a predictive biomarker of anti-PD-L1/PD1 therapy. While urothelial carcinoma (UC) patients with predominant or...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Surg Pathol
Autors principals: Reis, Henning, Serrette, Rene, Posada, Jennifer, Lu, Vincent, Chen, Ying-bei, Gopalan, Anuradha, Fine, Samson W., Tickoo, Satish K., Sirintrapun, S. Joseph, Iyer, Gopa, Funt, Samuel A., Teo, Min Yuen, Rosenberg, Jonathan E., Bajorin, Dean F., Dalbagni, Guido, Bochner, Bernard H., Solit, David B., Reuter, Victor E., Al-Ahmadie, Hikmat A.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561805/
https://ncbi.nlm.nih.gov/pubmed/31135485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAS.0000000000001264
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars